LobbyingAlliance for Mrna Medicines lobbying by quarter
Alliance for Mrna Medicines's latest lobbying report covers Q2 2026, at $40K. The four quarters Q3 2025–Q2 2026 total $170K. Its first report covers Q2 2025; the issues it reports most are Health Issues.
Alliance for Mrna Medicines
- Latest quarter
- $40K
- Q2 2026 · 1 reports
- Last 12 months
- $170K
- Last 4 quarters
- vs last quarter
- −33.3%
- Q2 2026 against the quarter before
- First report
- Q2 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2025 | $20K | 1 |
| Q3 2025 | $10K | 1 |
| Q4 2025 | $60K | 1 |
| Q1 2026 | $60K | 1 |
| Q2 2026 | $40K | 1 |
Policy issues the reports name
- Health issues5 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES5 reports
- SENATE5 reports
Firms it paid
| Firm | ||
|---|---|---|
| Leavitt Partners | $190K | 5 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ROBERT CLAYTON ALSPACH | Chief Health Counsel for Chairman - House E&C Committee (E&C);Counsel - E&C, Clerk - E&C, and Paid Intern - E&C | Q2 2026 |
| SARA SINGLETON | Deputy Assistant Secretary-HHS; Policy Advisor- Senate; Legislative Assistant- Senate; Policy Fellow- Senate | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/15for Q2 | Leavitt Partners | $40K |
| 04/20for Q1 | Leavitt Partners | $60K |
| 01/09for Q4 2025 | Leavitt Partners | $60K |
| 25/10/20for Q3 2025 | Leavitt Partners | $10K |
| 25/07/18for Q2 2025 | Leavitt Partners | $20K |
| 25/07/10for Q2 2025 | Leavitt Partners | Under $5,000 |